Aim- Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear. The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib. Methods- The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st January 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% C. I was calculated using StatsDirect Statistical analysis software V.3. Results A total of 18 studies containing 3,537 patients (male-1912 and female-1478) were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high. Conclusion: The physician should also take care of anemia while treating CML patients with imatinib. Anemia is a major concern associated with CML patients treated with Imatinib.